Skip to content

Advertisement

Volume 16 Supplement 3

Sepsis 2012

  • Poster presentation
  • Open Access

Estimation of efficacy early selective LPS sorption in patients with septic shock

  • 1,
  • 1 and
  • 1
Critical Care201216 (Suppl 3) :P75

https://doi.org/10.1186/cc11762

  • Published:

Keywords

  • Dopamine
  • Septic Shock
  • Early Initiation
  • Oxygenation Index
  • Recent Improvement

Background

Recent improvements in the treatment of severe Gram-negative sepsis have not resulted in a substantial decrease in mortality. LPS, originating from Gram-negative bacteria, is a major mediator in the development of septic shock [1]. Decreasing the load of LPS in these patients may be beneficial for these patients. The Alteco LPS Adsorber® selectively binds the lipid A moiety of LPS. Positive effects of the adsorber have been reported [24].

Methods

Nineteen patients with Gram-negative sepsis were treated with the Alteco LPS Adsorber®, in addition to standard therapy according to SSC Guidelines 2008. All patients needed inotropic support and mechanical lung ventilation. The mean APACHE II score at the start of treatment was 25.9 ± 1.8. The time to initiating the perfusion varied between 1.7 and 8.6 hours after the diagnosis of septic shock. The treatment lasted 120 minutes and was repeated after 24 hours. The SOFA score, oxygenation index (PaO2/FiO2) and the dose of dopamine was noted before and 48 hours after the treatment.

Results

At baseline, the severity of MODS was SOFA score 9.2 ± 2.8. At 48 hours the mean score SOFA was 4.3 ± 2.7, at the expense of an increase in the index of oxygenation from 128.6 ± 36.2 to 253.5 ± 44.8; and a decrease in doses of inotropic support (dopamine) from 17.1 ± 1.8 mkg/kg/minute to 4.2 ± 1.8 mkg/kg/minute. We found an inverse correlation between the time to initiate treatment with the adsorbtion and the decrease in SOFA score (R = -0.69; P < 0.1) (Figure 1). The degree of reduction of MODS depending on time of initiation of therapy is shown in Figure 2. The 28-day mortality was 26.3% in this patient group. There were no adverse events related to use of the adsorber.
Figure 1
Figure 1

Correlation between the SOFA score after 48 hours observation and the time of LPS adsorption start.

Figure 2
Figure 2

Reducing the degree of MODS as compared with the starting time of LPS adsorption (% of baseline).

Conclusion

Since LPS is a major mediator in Gram-negative sepsis, there is a rationale for rapid removal of LPS from patients with sepsis. Early initiation of LPS adsorption is most effective for reducing the signs of MODS. Our experiences with the use of Alteco LPS Adsorber® are promising as shown by our data above and are in support of previous findings [24]. The results are limited by the lack of controls; however, we believe that further randomized controlled clinical studies using this therapy are warranted, more so in view of the fact that no specific treatment against septic shock is available.

Authors’ Affiliations

(1)
Vishnevsky Institute Of Surgery, Burn Center, Moscow, Russia

References

  1. Marshall JC, et al.: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004, 190: 527-534. 10.1086/422254View ArticlePubMedGoogle Scholar
  2. Kulabukhov V: Use of novel technique for adsorption of lipopolysaccharide in the combined treatment of patients with severe organ negative sepsis [abstract 78]. Sepsis 2008; An International Sepsis Symposium; Paris. FranceGoogle Scholar
  3. Kulabukhov V, Chizhov A, Kleuzovich A, Kudryavtsev A: Clinical effects of adsorption of lipopolysaccharide in the treatment of Gram-negative severe sepsis. Crit Care 2010, 14(Suppl 2):P28. 10.1186/cc9131PubMed CentralView ArticleGoogle Scholar
  4. Ala-Kokko TI, Laurila J, Koskenkari J: A new endotoxin adsorber in septic shock: observational case series. Blood Purif 2011, 32: 303-309. 10.1159/000330323View ArticlePubMedGoogle Scholar

Copyright

© Kulabukhov et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement